Antengene Receives IND Approval for P-III SIENDO Trial of XPOVIO (Selinexor) to Treat Advanced or Recurrent Endometrial Cancer in China

 Antengene Receives IND Approval for P-III SIENDO Trial of XPOVIO (Selinexor) to Treat Advanced or Recurrent Endometrial Cancer in China

Shots:

  • The NMPA has approved the IND application for the P- III SIENDO trial to evaluate the safety and efficacy of selinexor for advanced or recurrent endometrial cancer. The trial is being conducted over 80 centers across North America, Europe, and Asia and the results are expected in H2’2021
  • Antengene holds the exclusive development and commercial rights for the therapy in Asia-Pacific markets and is currently conducting 5 clinical trials of selinexor for the treatment of MM, DLBCL, NSCLC and peripheral T & NK/T-cell lymphoma
  • Selinexor is first in class oral selective inhibitor and 1st FDA-approved drug for use in both MM and DLBCL. The company has submitted NDAs for therapy in Asia Pacific markets

Click here to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post